证券代码：002422 证券简称：科伦药业 公告编号：2014-070 四川科伦药业股份有限公司 2014 年第三季度报告正文 四川科伦药业股份有限公司 2014 年第三季度报告正文 1 四川科伦药业股份有限公司 2014 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 公司负责人刘革新、主管会计工作负责人赖德贵及会计机构负责人(会计主管人员)赖德贵声明：保证 季度报告中财务报表的真实、准确、完整。 2 除下列董事外，其他董事亲自出席了审议本次季报的董事会会议 未亲自出席董事姓名 未亲自出席董事职务 未亲自出席会议原因 被委托人姓名 程志鹏 董事 出差 潘慧 于明德 董事 出差 刘思川 四川科伦药业股份有限公司 2014 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | ...

Financial Performance - The company reported a revenue of 1.2 billion CNY for the first half of 2014, representing a year-on-year increase of 15%[19]. - The net profit attributable to shareholders was 200 million CNY, up 10% compared to the same period last year[19]. - The company achieved a revenue of CNY 3,967,165,098, representing a year-on-year increase of 24.70%[20]. - Net profit attributable to shareholders was CNY 536,876,748, a slight increase of 0.47% compared to the previous year[20]. - The company reported a diluted earnings per share of CNY 1.12, reflecting a 0.90% increase year-on-year[20]. - The company reported a significant increase in investment income, rising by 989.28% to ¥2,268,156 from ¥208,225[35]. - The net profit from the Pearl Pharmaceutical (Anyue Branch) Phase II expansion project was CNY 4.5528 million, which is lower than the expected benefits outlined in the prospectus[79]. - The net profit from the Yueyang project in Hunan was lower than expected due to the short production time and gradual capacity release[80]. - The net profit attributable to shareholders for the first three quarters of 2014 is expected to range from 84,876,000 to 101,851,000 CNY, representing a change of 0.00% to 20.00% compared to the same period in 2013[96]. Research and Development - The company plans to invest 300 million CNY in R&D for new drug development in the upcoming year[19]. - The company has 209 ongoing research projects, with 55 new projects initiated in 2014, including intravenous drugs and innovative drug delivery technologies[37]. - The company plans to submit approximately 30 new projects in the second half of 2014, with 16 projects already submitted in the first half[38]. - The company holds 1,203 patents, including 144 invention patents, and has been recognized as a national high-tech enterprise[29]. - The company plans to enhance its product structure and continue R&D in infusion products to maintain its leading position in the market[32]. - The company has established a complete R&D system from raw material synthesis to project registration, enhancing its research and development efficiency[65]. - The research institute currently has over 340 drug researchers, including 34 PhDs and 121 master's degree holders, with plans to expand to over 1,000 personnel in the next 2-3 years[65]. Market Expansion - User data indicates a 20% increase in the number of prescriptions filled for the company's products in the first half of 2014[19]. - The company has expanded its market presence by entering three new provinces, increasing its distribution network by 25%[19]. - The company is actively expanding its market presence in new packaging types, such as PP soft bags, to stabilize overall gross margins despite competitive pricing pressures in the infusion market[50]. - The company has received registration approvals for new infusion products, including PP bags, from several production bases, laying a solid foundation for product upgrades[54]. - The company is currently under investigation by the China Securities Regulatory Commission for alleged information disclosure violations[30]. Financial Management - The company has no plans to distribute cash dividends for this fiscal year, focusing instead on reinvestment[3]. - Future guidance estimates a revenue growth of 12% for the second half of 2014, driven by new product launches[19]. - The company has established a significant investment plan post-IPO to support its strategic development and enhance its competitive position in the antibiotic industry[61]. - The total amount of raised funds is ¥478,884.23 million, with ¥454,890.93 million already invested cumulatively[75]. - The company has committed to a total of CNY 149,107.33 million in various projects, with CNY 112,017.11 million already utilized[78]. - The company has made several equity acquisitions, including CNY 24,650 million for Zhejiang Guojing and CNY 42,600 million for Junjian Plastic[79]. Operational Efficiency - The gross margin for the first half of 2014 was reported at 45%, a slight decrease from 47% in the previous year[19]. - Operating costs increased to ¥2,297,385,511, a rise of 31.78%, primarily due to expanded operational scale and lower capacity utilization during the trial production phase of the thiocyanate erythromycin production line[35]. - The company has implemented lean management across ten production facilities, resulting in over 100 lean projects and a 70% implementation rate of 5S practices[52]. - The company has focused on quality management improvements post-GMP certification, enhancing risk control and product safety measures[51]. - The company has adjusted its marketing strategy and product structure in response to changes in market conditions affecting product sales prices[79]. Compliance and Governance - The company is currently under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure regulations related to transactions with a related party[111]. - The company received an administrative penalty from the China Securities Regulatory Commission on June 3, 2014, due to undisclosed related party transactions, resulting in fines and warnings[110]. - The company has taken corrective measures in response to the China Securities Regulatory Commission's directives regarding information disclosure and related party transactions[107]. - The company has made commitments to ensure no high-risk investments for twelve months following the replenishment of working capital[136]. - The company has committed to maintaining the independence of its operations and securing raw material supplies for its antibiotic projects[136]. Shareholder Information - The profit distribution plan for 2013 includes a cash dividend of RMB 2.50 per 10 shares and a capital reserve conversion of 5 shares for every 10 shares held, approved by the shareholders' meeting on May 21, 2014[100]. - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[103]. - The total number of ordinary shareholders at the end of the reporting period was 30,172[144]. - The number of shares with limited sale conditions decreased by 633,780, resulting in a total of 243,408,400 shares, representing 50.71% of total shares[144]. - The number of shares with unlimited sale conditions increased by 633,780, resulting in a total of 236,591,600 shares, representing 49.29% of total shares[144].

Financial Performance - The company's operating revenue for 2013 was CNY 6,831,281,981, representing a 16.07% increase compared to CNY 5,885,278,617 in 2012[22]. - The net profit attributable to shareholders for 2013 was CNY 1,079,521,586, a slight decrease of 0.74% from CNY 1,087,515,748 in 2012[22]. - The net cash flow from operating activities increased significantly by 160.79% to CNY 1,050,373,845 from CNY 402,771,467 in 2012[22]. - The total assets at the end of 2013 reached CNY 17,946,851,434, up 20.2% from CNY 14,930,778,241 at the end of 2012[22]. - The net assets attributable to shareholders increased by 10.87% to CNY 9,759,926,168 from CNY 8,802,834,955 at the end of 2012[22]. - The basic earnings per share for 2013 was CNY 2.25, a decrease of 0.88% from CNY 2.27 in 2012[22]. - The weighted average return on equity for 2013 was 11.64%, down from 13.11% in 2012[22]. - The company’s total cost of sales was CNY 3,712,055,490, marking a 10.01% increase from CNY 3,374,228,753 in 2012[82]. - Financial expenses rose by 77.61% to CNY 163,664,500, primarily due to increased debt from bonds and bank loans[85]. Dividend Policy - The company plans to distribute a cash dividend of 2.50 CNY per 10 shares (including tax) to all shareholders based on the total share capital as of December 31, 2013[4]. - The company has maintained a consistent cash dividend policy, distributing a total of 120 million yuan in cash dividends for 2013, which is 11.12% of the net profit attributable to shareholders[159]. - The proposed profit distribution for 2013 includes a cash dividend of 2.5 yuan per 10 shares and a capital reserve increase of 5 shares per 10 shares[160]. - The company has successfully implemented cash dividends for three consecutive years since its listing, reflecting a commitment to investor returns[156]. - The company has established a comprehensive cash dividend policy that meets regulatory requirements and enhances shareholder engagement[154]. Research and Development - The company invested over 400 million yuan in R&D in 2013, an increase of approximately 99.74% compared to the previous year[36]. - The company has a total of 557 product varieties with 924 specifications, including 108 varieties of infusion products[33]. - By the end of 2013, the company held 1,144 patents, including 126 invention patents[33]. - The company registered 55 projects in 2013, with 42 classified as A-class projects, focusing on areas such as oncology and diabetes[43]. - The company is actively pursuing new product development, with a total of 40 products listed for production or clinical trial applications, indicating a robust pipeline[47]. - The company aims to enhance its market position in oncology with several first generic drugs, including Afatinib and Cabazitaxel, currently in the clinical trial phase[46]. - The company has submitted applications for several electrolyte replenishment products, such as Sodium Acetate Ringer's Injection, to strengthen its portfolio in this area[46]. - The company is focusing on expanding its product line in the diabetes treatment sector, with several first generic drugs submitted for clinical trials, including Saxagliptin and Canagliflozin[46]. Internal Control and Governance - The company reported significant internal control deficiencies regarding the identification of related party transactions, impacting the accuracy and completeness of financial statements[5]. - The company plans to enhance internal control and governance in response to an investigation by the China Securities Regulatory Commission[34]. - The company has acknowledged the need for corrective measures and is actively working to address the issues raised by the regulatory authorities[197]. - The company is committed to enhancing compliance and governance by reinforcing the understanding of relevant laws and regulations among its board and management[200]. - The company plans to re-evaluate the decision-making process for related party transactions to ensure compliance with accounting standards and protect minority shareholders[197]. Market and Industry Risks - The company faces risks including industry policy changes, rising production costs, and risks associated with rapid development and fixed asset depreciation[13]. - The company faces risks from industry policy changes and rising production costs, which may impact procurement, manufacturing, and sales[145][146]. - Increased depreciation from new fixed assets is expected to affect profit levels, but the company plans to offset this through product sales[149]. Strategic Initiatives - The company has established a comprehensive product line with 155 ongoing projects, including 48 super A-class projects[42]. - The company aims to maintain its leading position in the infusion market through continuous industrial upgrades and product structure adjustments[32]. - The company is focused on expanding its antibiotic production chain, with the Yili Chuaning project as the leading initiative[131]. - The company plans to enhance its quality management system post-GMP certification, addressing potential quality risks across production facilities[138]. - The company is committed to developing high-quality generic drugs to address major disease treatment issues[133]. Compliance and Regulatory Issues - The company has been under scrutiny for failing to accurately disclose related party transactions, leading to a warning from the Sichuan Regulatory Bureau[197]. - The audit report from KPMG Huazhen provided a qualified opinion on the company's financial statements for 2013, reflecting concerns about the accuracy of disclosures[193]. - The company is required to submit a written report to the Sichuan Regulatory Bureau by May 31, 2013, detailing corrective actions taken in response to the regulatory findings[197]. - The company faced regulatory scrutiny due to non-compliance in the acquisition process, resulting in penalties for several executives, including a fine of 30,000 yuan for the chairman[199]. Acquisitions and Investments - Sichuan Kelun Pharmaceutical Co., Ltd. acquired the original Qingfa Pharmaceutical for a total payment of 148 million yuan, which was considered as settling all debts owed by the original Qingfa Pharmaceutical to Sangwei Biological Company[167]. - The company approved the acquisition of Chongzhou Junjian Plastic Co., Ltd. with a unanimous vote of 5 in favor and 0 against during the board meeting[198]. - The company has completed the absorption merger of Guizhou Jinlun on February 28, 2013, following the approval from the board on November 17, 2012[175]. - The company has dissolved Sichuan Yaobao due to reduced demand for glass bottles, which will not significantly impact overall business development and profitability[126]. Social Responsibility - The company has actively fulfilled its social responsibilities, publishing reports on governance, safety, and environmental protection[160]. - The company does not belong to any heavily polluting industries as defined by national environmental protection regulations[161]. - The company reported no significant social security issues during the reporting period[162]. - There were no administrative penalties imposed on the company during the reporting period[162].

四川科伦药业股份有限公司 2014 年第一季度报告正文 证券代码：002422 证券简称：科伦药业 公告编号：030 四川科伦药业股份有限公司 2014 年第一季度报告正文 1 四川科伦药业股份有限公司 2014 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人刘革新、主管会计工作负责人冯伟及会计机构负责人(会计主管 人员)赖德贵声明：保证季度报告中财务报表的真实、准确、完整。 2 除下列董事外，其他董事亲自出席了审议本次季报的董事会会议 未亲自出席董事姓名 未亲自出席董事职务 未亲自出席会议原因 被委托人姓名 刘思川 董事 出差 潘慧 董事 出差 于明德 董事 出差 张强 董事 出差 四川科伦药业股份有限公司 2014 年第一季度报告正文 第二节 主要财务数据及股东变化 非经常性损益项目和金额 √ 适用 □ 不适用 单位：元 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 ...